Showing 99 Results
People are different and their health needs vary. Though differences among patients are common, these differences aren’t always considered in treatment and coverage decisions.
An Institute for Clinical and Economic Review report acknowledges that patients are still facing barriers to needed treatments as a result of their health benefit design.
The Pharmacy Quality Alliance, with support from NPC, developed a framework that defines a patient’s medication access journey and characterizes barriers frequently encountered while seeking…
NPC President and CEO John M. O'Brien writes about how we can better incorporate the needs of caregivers into our health care system and provide them the support they deserve.
- Elements of Value
Mitigating racial health disparities is critical to advancing equitable access to health care, including medications and other therapies. NPC joined other experts at an AMCP Partnership Forum earlier…
In honor of World Heart Day, NPC looks at how innovative medical interventions have vastly improved cardiovascular disease outcomes.
This paper focuses on recognizing methodological flaws in RWE studies so that researchers can avoid these flaws by identifying them ahead of time – not just after a study is complete.
- Real-World Evidence
Researchers from Brigham and Women’s Hospital, Harvard Medical Center and NPC found that the potential for biased findings in RWE studies increases substantially in the absence of a rigorous and…
- Real-World Evidence
In a commentary for PharmaBoardroom, NPC's John M. O’Brien explains why we need a focused effort from all health care stakeholders to innovate on how we pay for vital medicines.
Reforming health benefits by overhauling existing utilization management practices and adjusting patient cost-sharing to incentivize high-value care would help achieve more affordable, patient…
What's at risk if we limit innovation? Read the commentary from NPC's John O'Brien in Chain Drug Review.
During a recent webinar, NPC President and CEO John M. O'Brien discusses how the Medicare Part D rebate system creates barriers to affordable care for patients.
A new study in JMCP found that patient input is rarely sought for coverage policies – although plans had processes to engage physicians and medical societies when developing coverage policies, no…
A new study by NPC and the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center found that health insurance plans do not ask patients for input when developing specialty drug…
Michael Ciarametaro, Vice President of Research at NPC, reflects on how the scientific revolution of hepatitis C led to a corresponding reimbursement revolution that became a fertile ground for large…
NPC Board Chair Michael Ryan says John M. O’Brien’s arrival as the new president and CEO of NPC reinforces a vital role the biopharmaceutical industry can play in the ongoing debate about health care…
- NPC News
It's possible to strike a balance between innovation and efficient spending, and to implement policies ensuring that resources are being invested in treatments, procedures and public health efforts…
This white paper provides key health care stakeholders, including clinicians, researchers, payers and regulators, with a broad view of how the COVID-19 pandemic may have impacted real-world data (RWD…
- Real-World Data
Thanks to an IRS rule, high-deductible health plans with health savings accounts can now cover an expanded list of preventive services and drugs before patients meet their plan’s annual out-of-pocket…
Stakeholders met virtually for an AMCP Partnership Forum to discuss viable solutions to challenges facing people living with rare disorders, such as affordable and timely access to therapies,…